Abstract | BACKGROUND: METHOD: RESULTS: Intent-to-treat analyses based on the Hamilton Depression Rating Scale revealed a response rate of 50% and a remission rate of 43% following augmentation with S-adenosyl-L-methionine. Gastrointestinal symptoms and headaches were the most common side effects. CONCLUSION:
|
Authors | Jonathan E Alpert, George Papakostas, David Mischoulon, John J Worthington 3rd, Timothy Petersen, Yasmin Mahal, Alana Burns, Teodoro Bottiglieri, Andrew A Nierenberg, Maurizio Fava |
Journal | Journal of clinical psychopharmacology
(J Clin Psychopharmacol)
Vol. 24
Issue 6
Pg. 661-4
(Dec 2004)
ISSN: 0271-0749 [Print] United States |
PMID | 15538131
(Publication Type: Clinical Trial, Comparative Study, Controlled Clinical Trial, Journal Article)
|
Chemical References |
- Cyclohexanols
- Serotonin Uptake Inhibitors
- adenosyl-methionine 1,4-butanedisulfonate
- Venlafaxine Hydrochloride
- S-Adenosylmethionine
|
Topics |
- Adult
- Cyclohexanols
(therapeutic use)
- Depressive Disorder, Major
(drug therapy, psychology)
- Drug Therapy, Combination
- Female
- Humans
- Male
- Middle Aged
- Psychiatric Status Rating Scales
(statistics & numerical data)
- S-Adenosylmethionine
(analogs & derivatives, therapeutic use)
- Selective Serotonin Reuptake Inhibitors
(therapeutic use)
- Venlafaxine Hydrochloride
|